Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | HTR7 | P34969 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202680 | 0.79 | KDM4E (0.38) | TLR9TLR8TLR7ALDH1A1PDE2A | |
| SCHEMBL3954742 | 0.78 | CHRM2 (0.45) | HRH3KMT2ATLR9TLR8TLR7 | |
| SCHEMBL17828176 | 0.75 | ALDH1A1 (0.41) | ACHEHTR7HRH3ALDH1A1 | |
| SCHEMBL15214346 | 0.74 | HTR7 (0.52) | ACHEHTR7HRH3ALDH1A1 | |
| SCHEMBL14375256 | 0.72 | TRPV6 (0.58) | ACHEHTR7HRH3TLR9TLR8 | |
| SCHEMBL17828162 | 0.72 | ACHE (0.55) | ACHEHRH3KMT2AALDH1A1 | |
| SCHEMBL29632608 | 0.71 | ACHE (0.54) | ACHEHTR7HRH3KMT2AALDH1A1 | |
| SCHEMBL26844932 | 0.69 | ALDH1A1 (0.51) | ACHEHRH3KMT2AALDH1A1 | |
| SCHEMBL17828161 | 0.69 | KDM4E (0.50) | ACHEHTR7HRH3 | |
| SCHEMBL17828169 | 0.69 | CCR5 (0.52) | ACHEHTR7HRH3TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | ACHE 1829/4885HTR7 425/4885HRH3 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.